Michael Amatangelo

Bristol-Myers Squibb (Germany) — Germany

Medicine · Health Sciences

21h-index3.1kcitations103works1.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(75), Protein Degradation and Inhibitors(58), Peptidase Inhibition and Analysis(21), Histone Deacetylase Inhibitors Research(16), Cancer Mechanisms and Therapy(9)

Publications103 total

Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma
Blood Neoplasia·2025Open Access
Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models
Blood·2025Open Access
Selinexor, mezigdomide, and dexamethasone in patients with Relapsed/Refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: Stomp Phase 1 results
Blood·2025Open Access
Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study
Blood·2025Open Access
Mezigdomide overcomes CRBN mutations emerging post IMiD therapy
Blood·2025
Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant-ineligible newly diagnosed multiple myeloma treated with iberdomide, daratumumab, and dexamethasone from the CC-220-MM-001 trial
Blood·2025
An Integrated Spatial and Single-Cell Multiomics Platform for Translational Research in Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
Iberdomide (Iber) Treatment (Tx) Enhances Manufactured Chimeric Antigen Receptor (Car) T Cell Expansion And Functionality And Is Immunostimulatory In Patients Post-Car T Cell Therapy
Clinical Lymphoma Myeloma & Leukemia·2025
Iberdomide, Daratumumab, and Dexamethasone (IberDd) in Transplant-Ineligible/Deferred (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Updated Results from the CC-220-MM-001 Trial
Clinical Lymphoma Myeloma & Leukemia·2025
MM-101: Iberdomide (IBER), Daratumumab (DARA), and Dexamethasone (DEX) (IberDd) in Transplant-Ineligible (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Results From the Phase 1/2 CC-220-MM-001 Trial
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: MM-101 Iberdomide (IBER), Daratumumab (DARA), and Dexamethasone (DEX) (IberDd) in Transplant-Ineligible (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Results From the Phase 1/2 CC-220-MM-001 Trial
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: MM-100 Iberdomide (IBER), Daratumumab (DARA), and Dexamethasone (DEX) (IberDd) Shows Deep Antimyeloma Activity Across Molecular Patient Subsets With Transplant-Ineligible (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Results From the Phase 1/2 CC-220-MM-001 Trial
Clinical Lymphoma Myeloma & Leukemia·2025
MM-100: Iberdomide (IBER), Daratumumab (DARA), and Dexamethasone (DEX) (IberDd) Shows Deep Antimyeloma Activity Across Molecular Patient Subsets With Transplant-Ineligible (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Results From the Phase 1/2 CC-220-MM-001 Trial
Clinical Lymphoma Myeloma & Leukemia·2025
Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): Updated results from the CC-220-MM-001 trial.
Journal of Clinical Oncology·2025
EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma
Future Oncology·2025· 1 citedOpen Access
Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma
Blood·2024· 2 cited
Iberdomide, Daratumumab, and Dexamethasone Shows Deep Antimyeloma Activity across Molecular Patient Subsets with Transplant-Ineligible Newly Diagnosed Multiple Myeloma from the CC-220-MM-001 Trial
Blood·2024· 4 citedOpen Access
Elotuzumab-Iberdomide-Dexamethasone Combination Therapy Activates T and NK Cells within the Immune Microenvironment of Multiple Myeloma Patients
Blood·2024
Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide
Blood·2024· 2 cited
OA-55 Iberdomide, Daratumumab, and Dexamethasone (IberDd) in Transplant-Ineligible (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Results From the CC-220-MM-001 Trial
Clinical Lymphoma Myeloma & Leukemia·2024· 1 cited
page 1 of 6Next →

Frequent Co-authors

Anjan Thakurta(24), Chad C. Bjorklund(16), Sagar Lonial(11), Albert Oriol(11), Paul G. Richardson(11), Anita K. Gandhi(10), Paulo Maciag(10), Jian Kang(9), William E. Pierceall(9), Jessica Katz(9), Niels W.C.J. van de Donk(8), Nizar J. Bahlis(8), Rakesh Popat(7), Sundar Jagannath(7), Teresa Peluso(7), Patrick R. Hagner(6), Ashraf Badros(6), Erin Flynt(6), Oliver Van Oekelen(6), Samir Parekh(6)